Medios stock
ILM1.DEXETRAMedios AG, HealthcareISIN DE000A1MMCC8WKN A1MMCC
50Score 50 out of 100, Neutral
Price and trend
56 / 100
Price history
−25% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 11% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 66).
The price is 36% below its 52-week high. Largest decline in 19 years: 95% (December 2007 to February 2010).
Chart figures for advanced users
- SMA 50$11.75
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$13.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)66
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.08
- The lowest closing price of the last twelve months.
- Resistance$19.19
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Medios AG belongs to the Medical (Distribution) industry (Germany) and, with a market value of $315.41M, is number 17 of 17 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.3B (up 10.4% year on year) and earnings of $17.03M (up 22.4%).
- For fiscal 2026, analysts expect on average revenue of $2.4B (up 4.1%) and adjusted earnings per share of $1.28 (up 92.8%).
Show more
- MEQIRI Score 50 out of 100 (Neutral): rank 374 of 702 in Healthcare, median 53.
- Our model puts fair value at $29.84, with the price 59% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 27.1% a year since 2020, Medical (Distribution) median 9.5%.Growth 68
- Below fair valuePrice 59% below the fair value of $29.84.Valuation 100
- Earnings turn into cashFree cash flow 214% of earnings over the last 12 months.Fundamentals 51
Weaknesses
- DilutionShare count up 62% since 2020.Capital allocation 24
- Interest barely coveredOperating profit covers interest only 2.2 times.Stability 63
Its standout strength is valuation, while capital allocation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak fundamentals
- high price swings
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $22.95 and expensive above $42.63 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.7%. At 9.7% the fair value would be $26.06, at 7.7% it would be $34.97.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 9.9% on the twelve months before. Revenue has grown strongly since 2012, at around 133% per year. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 4%, operating 2%, net 1%. From 2012 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 31 Mar 2027in 138 days
- Last reported
- 12 Aug 2026EPS reported $0.16
Analyst estimates
Earnings estimates have barely changed since 27 Oct 2026.
- Earnings per share
- $1.280.0%
- Revenue
- $2.4B0.0%
- Earnings per share
- $1.650.0%
- Revenue
- $2.49B0.0%
MEQIRI has stored the estimates since 27 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Medios
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Distribution)
The next larger companies by market value
- Asker Healthcare GroupASKER.ST $2.8B61
- Sopharma ADSPH.WA $1.88B57
- Redcare PharmacyRDC.DE $1.57B47
- UnipharUPR.IR $1.25B57
- Akso Health GroupAHG $1.15B35
- DocMorrisDOCM.SW $1.15B39
- ArjoARJO-B.ST $924.06M59
- Neuca S.a.NEU.WA $792.08M60
ETFs that hold Medios
Held by 1 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi SDAX UCITS ETF DistC005 | 0.48% | 0.70% | €158.8M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.